Technology
This technology is a novel platform for transcutaneous immunization based on a topical vaccine formulation applied directly to the skin.
The formulation combines imiquimod, dithranol (anthralin), and a suitable antigen epitope to induce strong cellular immune responses without invasive administration.
Dithranol acts as a co-adjuvant that enhances activation of antigen-presenting cells and promotes the release of immune-stimulatory cytokines, while imiquimod provides additional immune activation and the antigen epitope defines the disease-specific target.
Together, these components create a synergistic mechanism that drives efficient priming of CD4 and CD8 T cells and supports the generation of durable immune memory after topical administration.
